Sonntag, 1. August 2021
Navigation öffnen
Anzeige:
Imfinzi NSCLC
Imfinzi NSCLC
JOURNAL ONKOLOGIE – STUDIE
ACTengine

TCR-engineered T Cells in Solid Tumors

Rekrutierend

NCT-Nummer:
NCT03686124

Studienbeginn:
Mai 2019

Letztes Update:
12.07.2021

Wirkstoff:
IMA203 Product, Atezolizumab

Indikation (Clinical Trials):
Recurrence

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 1

Sponsor:
Immatics US, Inc.

Collaborator:
-

Studienleiter

Cedrik Britten, M.D.
Study Director
Immatics US, Inc.

Kontakt

Studienlocations
(3 von 7)

Onkologisches Zentrum Universitätsklinikum Würzburg
Josef-Schneider-Straße 6
97080 Würzburg
DeutschlandRekrutierend» Google-Maps
Ansprechpartner:

Phone: +49 931 201 0


Phone: +49 931 201 40953
» Ansprechpartner anzeigen
Alle anzeigen

Studien-Informationen

Detailed Description:

SCREENING: Patient eligibility will be determined by protocol inclusion/exclusion criteria

including HLA (human leukocyte antigen) screening and a biopsy for biomarker screening. If

the patient is eligible, white blood cells will be taken during leukapheresis for the

manufacture of the IMA203 product.

MANUFACTURING: IMA203 product will be made from the patient's white blood cells.

TREATMENT: Lymphodepletion with cyclophosphamide and fludarabine will occur in the days

before the IMA203 product infusion to improve the duration of time that IMA203 product stays

in the body. The patient will be admitted to the hospital during the T-cell infusion.

After the IMA203 product infusion, a low dose of IL-2 will be given subcutaneously daily for

10 days.

In Extension Cohort B (IMA203 plus atezolizumab), atezolizumab will be administered for up to

one year.

Patients will be monitored closely throughout the study. The treatment and observation phase

ends 3 years post infusion.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Pathologically confirmed advanced and/or metastatic solid tumor

- Patients may enter screening procedure before, during, or after the last available

indicated standard of care treatment. There is no limitation for prior anti cancer

treatments.

- Eastern Cooperative Oncology Group (ECOG) performance status 0-1

- HLA phenotype positive for the study

- Measurable disease and accessible to biopsy

- Adequate pulmonary function per protocol

- Adequate organ and bone marrow function per protocol

- Acceptable coagulation status per protocol

- Adequate hepatic function per protocol

- Adequate renal function per protocol

- Patient's tumor must express tumor antigen by qPCR using a fresh tumor biopsy specimen

- Life expectancy more than 3 months

- Confirmed availability of production capacities for IMA203 product

- Patients must have recurrent/progressing and/or refractory solid tumors and must have

received or not be eligible for all available indicated standard of care treatment.

- For hepatocellular carcinoma (HCC) patients only, Child-Pugh score of ≤ 6

- IMA203 product must have passed all of the release tests

- Female patient of childbearing potential must use adequate contraception prior to

study entry until 12 months after the infusion of IMA203

- Male patient must agree to use effective contraception or be abstinent while on study

and for 6 months after the infusion of IMA203

- Hepatocellular carcinoma (HCC) patients with liver cirrhosis only - upper endoscopy is

required within 6 months of study entry

- The patient must have recovered from any side effects of prior therapy to Grade 1 or

lower (except for non-clinically significant toxicities; e.g., alopecia, vitiligo)

prior to lymphodepletion. As determined by the investigator, the patient may still be

eligible if the patient has not fully recovered from Grade ≥ 2 toxicities if these

toxicities are not anticipated to further improve (e.g., chronic neuropathy) and such

toxicities are not anticipated to worsen with the lymphodepletion therapy

Exclusion Criteria:

- History of other malignancies (except for adequately treated basal or squamous cell

carcinoma or carcinoma in situ) within the last 3 years

- Solid tumors with low likelihood of tumor biomarker expression per protocol

- Pregnant or breastfeeding

- Serious autoimmune disease Note: At the discretion of the investigator, these patients

may be included if their disease is well controlled without the use of

immunosuppressive agents.

- History of cardiac conditions as per protocol

- Prior stem cell transplantation or solid organ transplantation

- Concurrent severe and/or uncontrolled medical disease that could compromise

participation in the study

- History of hypersensitivity to cyclophosphamide (CY), fludarabine (FLU), or IL-2 or

any of these rescue medications

- History of or current immunodeficiency disease or prior treatment compromising immune

function at the discretion of the treating physician

- HIV infection, active hepatitis B virus (HBV), active hepatitis C virus (HCV)

infection, ongoing active anti-HCV treatment or detectable HBV or HCV viral load at

the most recent laboratory report. Patients with both HBV and HCV infections will be

excluded from screening

1. Patients with a history of HCV infection and with an undetectable viral load per

the most recent laboratory report and/or completed anti-HCV treatment but are HCV

antibody positive are permitted.

2. History of treated HBV infection is permitted if the viral load is undetectable

per the most recent laboratory report. Note: HCC patients with controlled HBV

infection, as defined by resolved (anti-hepatitis B surface antigen [HBs-Ag]

antibody (Ab) negative, anti-core antigen [HBc Ag] Ab positive) or chronic stable

(anti HBs-Ag Ab positive) HBV infection will be eligible for screening. Patients

with active HBV infection who are not on anti-HBV treatment will be excluded.

- Any condition contraindicating leukapheresis, lymphodepletion, low-dose IL-2, and/or

IMA203 treatment

- Patients with active brain metastases

NOTE: Patients with a history of brain metastases may be eligible, if an imaging scan with

contrast enhancement not older than 4 weeks is able to exclude the existence of currently

active brain metastasis, and steroid therapy has been discontinued for ≥2 weeks.

- Treatment with protocol-defined excluded treatments, medical devices, and/or

procedures per protocol

- Concurrent participation in an interventional part of another clinical trial.

For atezolizumab treatment, patients must have adequate hematologic recovery, must have

recovered from infections to Grade 1 or lower, and must not have a history of severe

immune-related toxicities, defined as any Grade 3 or 4 toxicities related to prior

PD1/PD-L1 inhibitor therapy (e.g., atezolizumab, pembrolizumab or nivolumab etc.).

Studien-Rationale

Primary outcome:

1. Incidence of adverse events (AE) (Time Frame - up to 3 years post treatment)



Secondary outcome:

1. Persistence of T-cells (Time Frame - up to 3 years post treatment)

2. Tumor response per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 and immune-related RECIST (irRECIST) (Time Frame - up to 12 months)

Studien-Arme

  • Experimental: Dose Escalation
    Dose escalation of IMA203
  • Experimental: Extension Cohort A
    IMA203 at MTD
  • Experimental: Extension Cohort B
    IMA203 at MTD + atezolizumab

Geprüfte Regime

  • IMA203 Product:
    The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
  • IMADetect®:
    IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics clinical trials. IMADetect® is intended for investigational use only.
  • Atezolizumab (Tecentriq):
    Atezolizumab will be given post IMA203 infusion, after hematologic recovery is achieved, for up to a year after IMA203 infusion.

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
EHA 2021
  • SCD: Häufigere und längere VOC-bedingte Krankenhausaufenthalte nach Vorgeschichte von VOC-Hospitalisierungen – Ergebnisse einer Beobachtungsstudie
  • Real-World-Daten des ERNEST-Registers untermauern Überlebensvorteil unter Ruxolitinib bei primärer und sekundärer Myelofibrose
  • I-WISh-Studie: Ärzte sehen TPO-RAs als beste Option, um anhaltende Remissionen bei ITP-Patienten zu erzielen
  • Phase-III-Studie REACH2 bei steroidrefraktärer akuter GvHD: Hohes Ansprechen auf Ruxolitinib auch nach Crossover
  • SCD: Neues digitales Schmerztagebuch zur tagesaktuellen Erfassung von VOCs wird in Beobachtungsstudie geprüft
  • Französische Real-World-Studie: Eltrombopag meist frühzeitig nach ITP-Diagnose im Rahmen eines Off-label-Use eingesetzt
  • Fortgeschrittene systemische Mastozytose: Französische Real-World-Studie bestätigt klinische Studiendaten zur Wirksamkeit von Midostaurin
  • CML-Management weitgehend leitliniengerecht, aber verbesserungsfähig – Ergebnisse einer Querschnittsbefragung bei britischen Hämatologen
  • Britische Real-World-Studie: Kardiovaskuläres Risikomanagement bei MPN-Patienten in der Primärversorgung nicht optimal
  • Myelofibrose: Früher Einsatz von Ruxolitinib unabhängig vom Ausmaß der Knochenmarkfibrose